10/673,077
Lycook 10/15/07
updated search

d his

(FILE 'HOME' ENTERED AT 13:08:00 ON 15 OCT 2007)

FILE 'BIOSIS, CAPLUS, EMBASE, MEDLINE, JAPIO' ENTERED AT 13:08:29 ON 15 OCT 2007

L1 25648 S (MMP 9)
L2 44 S L1 AND VWF
L3 22 DUPLICATE REMOVE L2 (22 DUPLICATES REMOVED)
L4 1 S L3 AND PD<2001

ANSWER 1 OF 1 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AN 2001:35790 BIOSIS
DN PREV200100035790
TI Expression of 92-kDa type IV collagenase correlates with angiogenic markers and poor survival in head and neck squamous cell carcinoma.
AU Riedel, Frank [Reprint author]; Goette, Karl; Schwalb, Joachim; Bergler, Wolfgang; Hoermann, Karl
CS Klinikum, Univ.-HNO-Klinik, Theodor-Kutzer-Ufer, 68135, Mannheim, Germany
frank.riedel@hno.ma.uni-heidelberg.de
SO International Journal of Oncology, (December, 2000) Vol. 17, No. 6, pp. 1099-1105. print.
ISSN: 1019-6439.
DT Article
LA English
ED Entered STN: 10 Jan 2001
Last Updated on STN: 12 Feb 2002
AB MMP-9, which degrades extracellular matrix, is believed to play a crucial role in tumor invasion and metastasis. Angiogenesis is also perceived as an important step in tumor growth and metastasis. The aim of this study was to investigate the expression of MMP-9 in tumor samples of HNSCC patients and to study a possible correlation to angiogenic markers. Cryostat sections of 52 HNSCC tumors were immunostained for MMP-9, bFGF and VEGF using a standard streptavidin-biotin complex procedure for light microscopic investigation. Microvessel density (MVD) was determined by staining of endothelial cells immunohistochemically using anti-vWF monoclonal antibody. MMP-9 positive staining was detected in 27/52 (52%) of the tumors. MMP-9 immunoreactivity did not correlate with the main clinicopathological characteristics of the patients (localisation, T-stage, N-stage, histological grading), but correlated with worse survival of the patients. MMP-9 negative tumors showed a significant lower mean MVD per microscopic field than MMP-9 positive tumors ($p<0.001$). There was a significant association of MMP-9 and VEGF expression ($p<0.05$). The presence of MMP-9 in HNSCC cancer and the positive correlation with MVD and VEGF expression supports the theory that MMP-9 functions as a regulator of tumor angiogenesis supporting endothelial cell invasion. MMP-9 and VEGF might act co-operatively in the process of neovascularization in human head and neck cancer.
CC Gerontology - 24500
Cytology - Animal 02506
Cytology - Human 02508
Biochemistry studies - General 10060
Biochemistry studies - Proteins, peptides and amino acids 10064
Enzymes - General and comparative studies: coenzymes 10802
Cardiovascular system - Physiology and biochemistry 14504
Endocrine - General 17002
Neoplasms - Pathology, clinical aspects and systemic effects 24004
IT Major Concepts
Biochemistry and Molecular Biophysics; Cardiovascular System (Transport and Circulation); Tumor Biology
IT Parts, Structures, & Systems of Organisms
endothelial cells; head; neck
IT Diseases
head and neck squamous cell carcinoma: neoplastic disease
Head and Neck Neoplasms (MeSH); Carcinoma, Squamous Cell (MeSH)
IT Chemicals & Biochemicals
VEGF [vascular endothelial growth factor]: expression; angiogenic markers; anti-vWF monoclonal antibody [anti-von Willebrand factor monoclonal antibody]; bFGF [basic fibroblast growth factor]; matrix metalloproteinase-9: expression; type IV collagenase: 92-kDa, expression
IT Methods & Equipment

ANSWER 1 OF 1 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AN 2001:35790 BIOSIS
DN PREV200100035790
TI Expression of 92-kDa type IV collagenase correlates with angiogenic markers and poor survival in head and neck squamous cell carcinoma.
AU Riedel, Frank [Reprint author]; Goette, Karl; Schwalb, Joachim; Bergler, Wolfgang; Hoermann, Karl
CS Klinikum, Univ.-HNO-Klinik, Theodor-Kutzer-Ufer, 68135, Mannheim, Germany frank.riedel@hno.ma.uni-heidelberg.de
SO International Journal of Oncology, (December, 2000) Vol. 17, No. 6, pp. 1099-1105. print.
ISSN: 1019-6439.
DT Article
LA English
ED Entered STN: 10 Jan 2001
Last Updated on STN: 12 Feb 2002
AB MMP-9, which degrades extracellular matrix, is believed to play a crucial role in tumor invasion and metastasis. Angiogenesis is also perceived as an important step in tumor growth and metastasis. The aim of this study was to investigate the expression of MMP-9 in tumor samples of HNSCC patients and to study a possible correlation to angiogenic markers. Cryostat sections of 52 HNSCC tumors were immunostained for MMP-9, bFGF and VEGF using a standard streptavidin-biotin complex procedure for light microscopic investigation. Microvessel density (MVD) was determined by staining of endothelial cells immunohistochemically using anti-vWF monoclonal antibody. MMP-9 positive staining was detected in 27/52 (52%) of the tumors. MMP-9 immunoreactivity did not correlate with the main clinicopathological characteristics of the patients (localisation, T-stage, N-stage, histological grading), but correlated with worse survival of the patients. MMP-9 negative tumors showed a significant lower mean MVD per microscopic field than MMP-9 positive tumors ($p<0.001$). There was a significant association of MMP-9 and VEGF expression ($p<0.05$). The presence of MMP-9 in HNSCC cancer and the positive correlation with MVD and VEGF expression supports the theory that MMP-9 functions as a regulator of tumor angiogenesis supporting endothelial cell invasion. MMP-9 and VEGF might act co-operatively in the process of neovascularization in human head and neck cancer.
CC Gerontology - 24500
Cytology - Animal 02506
Cytology - Human 02508
Biochemistry studies - General 10060
Biochemistry studies - Proteins, peptides and amino acids 10064
Enzymes - General and comparative studies: coenzymes 10802
Cardiovascular system - Physiology and biochemistry 14504
Endocrine - General 17002
Neoplasms - Pathology, clinical aspects and systemic effects 24004
IT Major Concepts
Biochemistry and Molecular Biophysics; Cardiovascular System (Transport and Circulation); Tumor Biology
IT Parts, Structures, & Systems of Organisms
endothelial cells; head; neck
IT Diseases
head and neck squamous cell carcinoma: neoplastic disease
Head and Neck Neoplasms (MeSH); Carcinoma, Squamous Cell (MeSH)
IT Chemicals & Biochemicals
VEGF [vascular endothelial growth factor]: expression; angiogenic markers; anti-vWF monoclonal antibody [anti-von Willebrand factor monoclonal antibody]; bFGF [basic fibroblast growth factor]; matrix metalloproteinase-9: expression; type IV collagenase: 92-kDa, expression
IT Methods & Equipment

immunostaining: analytical method, staining method; light microscopy: microscopy method, microscopy: CB, microscopy: CT

IT Miscellaneous Descriptors
angiogenesis; microvessel density; survival; tumor invasion; tumor metastasis

ORGN Classifier
Hominidae 86215
Super Taxa
Primates; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
human: adult, aged, aged/80 and over, female, male, middle age, patient
Taxa Notes
Animals, Chordates, Humans, Mammals, Primates, Vertebrates

RN 146480-36-6 (matrix metalloproteinase-9)
9040-48-6Q (type IV collagenase)
146480-35-5Q (type IV collagenase)
146480-36-6Q (type IV collagenase)
106096-93-9 (BASIC FIBROBLAST GROWTH FACTOR)
127464-60-2 (VASCULAR ENDOTHELIAL GROWTH FACTOR)

=>

immunostaining: analytical method, staining method; light microscopy: microscopy method, microscopy: CB, microscopy: CT

IT Miscellaneous Descriptors
angiogenesis; microvessel density; survival; tumor invasion; tumor metastasis

ORGN Classifier
Hominidae 86215
Super Taxa
Primates; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
human: adult, aged, aged/80 and over, female, male, middle age, patient
Taxa Notes
Animals, Chordates, Humans, Mammals, Primates, Vertebrates

RN 146480-36-6 (matrix metalloproteinase-9)
9040-48-6Q (type IV collagenase)
146480-35-5Q (type IV collagenase)
146480-36-6Q (type IV collagenase)
106096-93-9 (BASIC FIBROBLAST GROWTH FACTOR)
127464-60-2 (VASCULAR ENDOTHELIAL GROWTH FACTOR)

=>

d his

(FILE 'HOME' ENTERED AT 13:08:00 ON 15 OCT 2007)

FILE 'BIOSIS, CAPLUS, EMBASE, MEDLINE, JAPIO' ENTERED AT 13:08:29 ON 15 OCT 2007

L1 25648 S (MMP 9)
L2 44 S L1 AND VWF
L3 22 DUPLICATE REMOVE L2 (22 DUPLICATES REMOVED)
L4 1 S L3 AND PD<2001

ANSWER 32 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1994:51584 CAPLUS

DN 120:51584

ED Entered STN: 05 Feb 1994

TI Changes of von Willebrand factor and antithrombin III levels in acute stroke: Difference between thrombotic and hemorrhagic stroke

AU Liu, Longbin; Lin, Zhusan; Shen, Zeshuang

CS 2nd Affil. Hosp., Hunan Med. Univ., Peop. Rep. China

SO Thrombosis Research (1993), 72(4), 353-8
CODEN: THBRAA; ISSN: 0049-3848

DT Journal

LA English

CC 14-6 (Mammalian Pathological Biochemistry)

AB In the present study, the authors measured plasma von Willebrand factor (vWF) levels, concns. and activities. of Antithrombin III (ATIII) in the acute phase of thrombotic and hemorrhagic stroke prior to any therapy. The authors' results demonstrate that vWF levels are increased in both thrombotic and hemorrhagic stroke, and that vWF and ATIII levels differ between thrombotic and hemorrhagic stroke in patients with high incidence of atherosclerosis.

ST von Willebrand antithrombin thrombotic hemorrhagic stroke

IT Brain, disease
(hemorrhagic stroke, antithrombin III and von Willebrand factor of blood plasma in, in human)

IT Brain, disease
(thrombotic stroke, antithrombin III and von Willebrand factor of blood plasma in, in human)

IT 109319-16-6
RL: BIOL (Biological study)
(of blood plasma, in human hemorrhagic and thrombotic stroke, antithrombin III in relation to)

IT 9000-94-6, Antithrombin III
RL: BIOL (Biological study)
(of blood plasma, in human hemorrhagic and thrombotic stroke, von Willebrand factor in relation to)

LV Cook 10/15/07

Day : Monday
Date: 10/15/2007
Time: 10:53:43

PALM INTRANET

Biotech Query for 10/673077

Title: **DIAGNOSTIC MARKERS OF STROKE AND CEREBRAL INJURY AND METHODS OF USE THEREOF**

Inventor: **VALKIRS, GUNARS**

Location:

Location Date: Group Art Unit: **1641**

Status: **71/RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER**

Barcode: Filing or 371(c) Date: **09/26/2003**

Num	Date	Code	Contents Description
51	11/15/2006	CRFE	CRF IS GOOD TECHNICALLY / ENTERED INTO DATABASE

Search for Biotech Info: Application# [] Search

PCT / [] / [] Search

Bar Code # [] Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

LYCook 10/15/07

PALM Intranet

Application Number Submit

IDS Flag Clearance for Application 10673077

IDS Information

Content	Mailroom Date	Entry Number	IDS Review	Last Modified	Reviewer
WIDS	2007-07-24	66	Y ☑	2007-10-15 10:53:13.0	LCook
WIDS	2007-05-29	63	Y ☑	2007-10-15 10:53:09.0	LCook
WIDS	2006-11-07	56	Y ☑	2007-05-09 00:00:00.0	CR #232884
WIDS	2006-04-24	41	Y ☑	2007-05-09 00:00:00.0	CR #232884
WIDS	2005-09-06	40	Y ☑	2007-05-09 00:00:00.0	CR #232884
WIDS	2005-06-27	38	Y ☑	2007-05-09 00:00:00.0	CR #232884
WIDS	2005-01-24	36	Y ☑	2007-05-09 00:00:00.0	CR #232884
WIDS	2004-11-24	34	Y ☑	2007-05-09 00:00:00.0	CR #232884
WIDS	2003-12-31	31	Y ☑	2007-05-09 00:00:00.0	CR #232884

Update